CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today the issuance of U.S. Patent No. 7,276,480, covering the composition of matter for its lead product candidate DX-88, a recombinant small protein discovered from the Company’s proprietary phage display technology, to which Dyax owns the worldwide rights. The recently issued patent will expire in 2023. Dyax now has a total of nine issued U.S. patents covering DX-88 as well as other related kallikrein inhibitors, and their uses.
